Shuttle Pharmaceuticals Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) on September 15, 2026, covering events occurring on September 9, 2026. The Company is an emerging growth company incorporated in Delaware. The report details the results of a Special Meeting of Stockholders held on September 9, 2026, where stockholders approved the issuance of specific securities as previously outlined in a Definitive Proxy Statement filed on August 13, 2026.
Key Financial Metrics and Capital Structure Changes
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. Instead, it reports significant changes to the Company's capital structure resulting from the approved issuance of unregistered securities:
- Common Stock Issued via Conversion: As of September 14, 2026, the Company issued 2,869,595 shares of Common Stock upon conversion of Series B-1 Preferred Stock and 867,887 shares upon conversion of Series B-2 Preferred Stock.
- Warrants Issued: The Company issued Common Stock Purchase Warrants to purchase approximately 927,114 shares. These are exercisable for three years at a price of $10.30 per share (post-reverse split).
- Pre-Funded Warrants Issued: The Company issued Pre-Funded Warrants to purchase approximately 16,932,508 shares of Common Stock.
- Ownership Limitations: The issuance of Common Stock from preferred conversions accounted for 4.99% beneficial ownership limitations.
Material Changes and Unusual Items
The primary material change reported is the execution of the capital raise approved by stockholders. The issuance of the securities described in Item 3.02 was not registered under the Securities Act of 1933, relying instead on the exemption from registration provided by Section 4(a)(2). The filing references a prior 8-K filed on May 1, 2026, for the specific terms of the Warrants and Pre-Funded Warrants.
Guidance, Outlook, and Risks
The filing text does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure regarding the unregistered nature of the securities issuance.
Key Facts for Investor Verification
- Verify the total number of outstanding shares post-conversion and the impact of the 16.9 million pre-funded warrants on potential dilution.
- Confirm the exercise price of $10.30 per share for the standard warrants and the terms of the pre-funded warrants referenced in the May 1, 2026 filing.
- Review the Definitive Proxy Statement (filed August 13, 2026) for the full context of the capital raise and the use of proceeds.
- Note that the Company is classified as an emerging growth company, which may affect financial reporting requirements.